Nyiregyhaza

• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended
  2023-503657-35-00 5 2023-10-10 Obesity
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended
  2023-503659-88-00 5 2023-09-05 Obesity
• A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 1 … Ended
  2022-502023-21-00 5 2023-07-12 Prevention of pregnancy
• A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest … Ended
  2022-502024-51-00 5 2023-07-12 Prevention of pregnancy
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 5 2023-06-05 Chronic Rhinosinusitis (CRS) in Adults
• A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended
  2023-509747-27-00 4 2023-05-18 Heart failure
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505902-40-00 4 2023-03-28 Heart Failure with Preserved Ejection Fraction
• A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events ( KRAKEN ) Ended
  2022-501466-21-00 4 2023-03-01 Lipoprotein Disorder
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I … Ended
  2023-507569-24-00 4 2022-06-20 Myocardial Infarction, Acute Heart Failure, Left Sided
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22 Chronic obstructive pulmonary disease (COPD)
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended
  2022-500752-39-00 5 2021-11-25 Prevention of Respiratory syncytial virus (RSV) infection in infants a
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction

Showing 121–144 of 157 trials